Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -66.47% is 42% above its 1-year average of -114.61%, near the high end of its 1-year range (-140.01%–-66.47%).
As of the fiscal period ended Tuesday, June 30, 2026. 42.01% above its 12-month average of -114.61%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -66.47%.
RETURN ON EQUITY (ROE)
-66.47%
RETURN ON EQUITY (ROE) AVG TTM
-114.61%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+42.01%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 651 covered companies
CURRENT VS SECTOR MEDIAN
-65.34%
vs the sector median at left
Filana Therapeutics, Inc.
Market Cap
$40.42M
Return on Equity (ROE)
-66.47%
TTM Avg
-114.61%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$40.28M
Return on Equity (ROE)
-83.03%
TTM Avg
-44.32%
3Y Avg
5.07%
5Y Avg
17.23%
Market Cap
$39.96M
Return on Equity (ROE)
14.51%
TTM Avg
6.28%
3Y Avg
-34.57%
5Y Avg
-35.24%
Market Cap
$39.08M
Return on Equity (ROE)
-140.36%
TTM Avg
-216.21%
3Y Avg
-112.57%
5Y Avg
-76.80%
Market Cap
$41.92M
Return on Equity (ROE)
-8.23%
TTM Avg
-18.98%
3Y Avg
-38.34%
5Y Avg
-43.89%
Market Cap
$38.35M
Return on Equity (ROE)
-28.65%
TTM Avg
-189.41%
3Y Avg
-194.44%
5Y Avg
-158.64%
Market Cap
$42.97M
Return on Equity (ROE)
-102.45%
TTM Avg
30.59%
3Y Avg
217.16%
5Y Avg
155.68%
Market Cap
$37.76M
Return on Equity (ROE)
-160.05%
TTM Avg
-184.57%
3Y Avg
-168.71%
5Y Avg
-141.15%
Market Cap
$43.96M
Return on Equity (ROE)
-161.19%
TTM Avg
-40.99%
3Y Avg
-40.41%
5Y Avg
-33.61%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Filana Therapeutics, Inc. (FLNA) | $40.42M | -66.47% | -114.61% | N/A | N/A |
| Metagenomi, Inc. Common Stock (MGX)vs › | $40.28M | -83.03% | -44.32% | 5.07% | 17.23% |
| Nephros, Inc. (NEPH)vs › | $39.96M | 14.51% | 6.28% | -34.57% | -35.24% |
| Harvard Bioscience, Inc. (HBIO)vs › | $39.08M | -140.36% | -216.21% | -112.57% | -76.80% |
| Precipio, Inc. (PRPO)vs › | $41.92M | -8.23% | -18.98% | -38.34% | -43.89% |
| Incannex Healthcare Limited (IXHL)vs › | $38.35M | -28.65% | -189.41% | -194.44% | -158.64% |
| BioStem Technologies, Inc. (BSEM)vs › | $42.97M | -102.45% | 30.59% | 217.16% | 155.68% |
| Edesa Biotech, Inc. (EDSA)vs › | $37.76M | -160.05% | -184.57% | -168.71% | -141.15% |
| Nano-X Imaging Ltd. (NNOX)vs › | $43.96M | -161.19% | -40.99% | -40.41% | -33.61% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.70M | -476.77% | -979.99% | -646.46% | -421.61% |
ROE
-66.5%
ROA
-40.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -66.47% |
| 2026-03-31 | -114.32% |
| 2025-12-31 | -122.27% |
| 2025-09-30 | -129.99% |
| 2025-06-30 | -140.01% |
